Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective β3-adrenergic receptor agonists

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 9, 2009, Pages 3283-3294

  Maruyama, Tatsuya ^a   Onda, Kenichi ^a   Hayakawa, Masahiko ^a   Seki, Norio ^a   Takahashi, Takumi ^a   Moritomo, Hiroyuki ^a   Suzuki, Takayuki ^a   Matsui, Tetsuo ^a   Takasu, Toshiyuki ^a   Nagase, Itsuro ^a   Ohta, Mitsuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

3 Adrenergic receptor; Acetanilide; Agonist; Diabetes; Phenoxypropanolamine

Indexed keywords

4' [2 ((2 HYDROXY 3 PHENOXYPROPYL)AMINO)PROPYL] 2 (1 BENZYLIMIDAZOL 2 YL) ACETANILIDE; 4' [2-((2 HYDROXY 3 PHENOXYPROPYL)AMINO)ETHYL] 2 (1 BENZYLIMIDAZOL 2 YL) ACETANILIDE; ACETANILIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; N METHYL 4' [2 ((2 HYDROXY 3 PHENOXYPROPYL)AMINO)ETHYL] 2 (1 BENZYLIMIDAZOL 2 YL)ACETANILIDE; PHENOXYPROPANOLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HYPOGLYCEMIA; MOUSE; NONHUMAN;

ACETANILIDES; ADRENERGIC BETA-1 RECEPTOR AGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENOXYPROPANOLAMINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA;

EID: 65249187351     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.03.044     Document Type: Article

References (25)

1. Nisoli E., Tonello C., and Carruba M.O. Curr. Med. Chem.: Cent. Nerv. Syst. Agents 3 (2003) 257
2. Moneva M.H., and Dagogo-Jack S. Curr. Drug Targets 3 (2002) 203
3. Arch J.R., Ainsworth A.T., Cawthorne M.A., Piercy V., Sennitt M.V., Thod V.E., Wilson C., and Wilson S. Nature 309 (1984) 163
4. Howe R. Drugs Future 18 (1993) 529
5. Cantello B.C.C., and Smith S.A. Drugs Future 16 (1991) 797
6. Bloom J.D., and Claus T.H. Drugs Future 19 (1994) 23
7. Arch J.R.S., and Wilson S. Int. J. Obesity 20 (1996) 191
8. Lipworth B.J. Br. J. Clin. Pharmacol. 42 (1996) 291
9. Emorine L.J., Marullo S., Briend-Sutren M.-M., Patey G., Tate K., Delavier-Klutchko C., and Strosberg A.D. Science 245 (1989) 1118
10. Emorine L.J., Feve B., Pairault J., Briend-Sutren M.-M., Nahmias C., Marullo S., Delavier-Klutchko C., and Strosberg A.D. Am. J. Clin. Nutr. 55 (1992) 215S
11. Tate K.M., Briend-Sutren M.-M., Emorine L.J., Delavier-Klutchko C., Marullo S., and Strosberg A.D. Eur. J. Biochem. 196 (1991) 357
12. Maruyama, T.; Onda, K; Hayakawa, M; Matsui, T; Takasu, T; Ohta, M. Eur. J. Med. Chem., in press.
13. Howe R. Drugs Future 18 (1993) 529
14. Hu B., and Jennings L.L. In: King F.D., and Oxford A.W. (Eds). Progress in Medicinal Chemistry Vol. 41 (2003), Elsevier Science B.V. 167-194
15. Fisher, M. H. Eur. Patent 611003, 1994.
16. Dingledine, R. J. PCT Int. WO2002072542, 2002.
17. Elsinga P.H., van Waarde A., Laeggi K.A., Schreiber G., Heldoorn M., and Vaalburg W. J. Med. Chem. 40 (1997) 3829
18. Amano, M. Jpn. Kokai Tokkyo Koho JP01287064, 1989.
19. +).
20. Jaeggi, K. A. Eur. Patent EP275821, 1987.
21. +).
22. Fisher, M. H. Eur. Patent EP611003, 1994.
23. +).
24. Cornforth J.W., and Cornforth R.H. J. Chem. Soc. (1947) 96
25. Borovicka M., Sedivy Z., Jilek J.O., and Protiva M. Collect. Czech. Chem. Commun. 20 (1955) 437